BioClean BarrierPlus™ Sterile Gauntlet - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

BioClean BarrierPlus™ Sterile Gauntlets (S-BBNG) are designed for use in highly controlled environments setting the standard for cleanliness and quality assurance.

Processed in an ISO Class 4 Cleanroom, BioClean BarrierPlus gauntlets have incredibly low levels of particulates and are packed in cleanroom compatible EasyTear™ packaging. Manufactured from white-coloured accelerator-free nitrile (a stretchy, synthetic rubber), they are resistant to a wide range of chemicals, including a selection of commonly-used chemotherapy drugs.  Nitrile also exhibits excellent ESD (Electrostatic Dissipative) properties.

Each BioClean BarrierPlus gauntlet is visually inspected for holes on five separate occasions throughout the manufacturing process, along with water and air pressure testing, to guarantee delivery of a gauntlet 100% free from holes.

BioClean BarrierPlus™ Sterile Gauntlets are available in lengths of up to 840mm (33”) and three port sizes from 150mm to 300mm (6.0” to 12”). 

Also available from the BioClean BarrierPlus range is a sterile mitten (S-BBNM) for use when interventions are rare and access speed is critical, and a sleeve (S-BBNS0) available in lengths of up to 660mm (26”), and suitable for port sizes from 150mm (6.0”) to 300mm (12”).  With a cuff diameter of 90mm (3.5”) the sleeves will fit the majority of available cuff ring systems.

Contact Details:
Nitritex Ltd
Minton Enterprise Park, Oaks Drive
Newmarket, Suffolk, CB8 7YY
www.bioclean.com, info@bioclean.com

Tel: +44 1638 663338
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
FindPharma Custom Search

Click here